{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:27:05Z","timestamp":1761618425867,"version":"build-2065373602"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cll.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T21:46:48Z","timestamp":1757540808000},"page":"675-689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Women\u2019s and Transgender Issues in Thrombosis and Hemostasis"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-2406","authenticated-orcid":false,"given":"Jameel","family":"Abdulrehman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela C.","family":"Weyand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cll.2025.07.007_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1530\/eje.0.1510259","article-title":"Estrogen increases coagulation factor V mRNA levels via both estrogen receptor-alpha and -beta in murine bone marrow\/bone","volume":"151","author":"Mov\u00e9rare","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.cll.2025.07.007_bib3","first-page":"21","article-title":"Oral contraceptive use among women aged 15 to 49: results from the Canadian health measures survey","volume":"26","author":"Rotermann","year":"2015","journal-title":"Health Rep"},{"issue":"1","key":"10.1016\/j.cll.2025.07.007_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/GME.0000000000000954","article-title":"Hormone therapy use in the Canadian longitudinal study on aging: a cross-sectional analysis","volume":"25","author":"Costanian","year":"2018","journal-title":"Menopause"},{"issue":"4 Suppl","key":"10.1016\/j.cll.2025.07.007_bib5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ajog.2011.06.056","article-title":"The state of hormonal contraception today: established and emerging noncontraceptive health benefits","volume":"205","author":"Maguire","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.cll.2025.07.007_bib6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1701-2163(16)34242-6","article-title":"Contraceptive use among Canadian women of reproductive age: results of a national survey","volume":"31","author":"Black","year":"2009","journal-title":"J Obstet Gynaecol Can"},{"issue":"7","key":"10.1016\/j.cll.2025.07.007_bib7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause society","volume":"29","author":"Advisory","year":"2022","journal-title":"Menopause"},{"issue":"10","key":"10.1016\/j.cll.2025.07.007_bib8","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jogc.2021.08.003","article-title":"Guideline No. 422a: menopause: vasomotor symptoms, prescription therapeutic agents, complementary and alternative medicine, nutrition, and lifestyle","volume":"43","author":"Yuksel","year":"2021","journal-title":"J Obstet Gynaecol Can"},{"issue":"2","key":"10.1016\/j.cll.2025.07.007_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1076029616683802","article-title":"Oral contraceptives and HRT risk of thrombosis","volume":"24","author":"Gialeraki","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"10.1016\/j.cll.2025.07.007_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12763","article-title":"Hormonal therapies and venous thrombosis: considerations for prevention and management","volume":"6","author":"LaVasseur","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2025.07.007_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0889-8545(21)00629-X","article-title":"Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery","volume":"21","author":"Baker","year":"1994","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"8","key":"10.1016\/j.cll.2025.07.007_bib12","article-title":"Hormone therapy in postmenopausal women and risk of endometrial hyperplasia","volume":"2012","author":"Furness","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cll.2025.07.007_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.maturitas.2016.05.013","article-title":"Hormone replacement therapy and the risk of endometrial cancer: a systematic review","volume":"91","author":"Sjogren","year":"2016","journal-title":"Maturitas"},{"issue":"7","key":"10.1016\/j.cll.2025.07.007_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of the North American menopause society","volume":"24","author":"NHTPSAP","year":"2017","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.cll.2025.07.007_bib15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/blood.V63.3.657.657","article-title":"Estrogen stimulates von Willebrand factor production by cultured endothelial cells","volume":"63","author":"Harrison","year":"1984","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cll.2025.07.007_bib16","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0735-1097(02)02565-2","article-title":"Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women","volume":"40","author":"Rabbani","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.cll.2025.07.007_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20123111","article-title":"Effects of estrogens on platelets and megakaryocytes","volume":"20","author":"Dupuis","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cll.2025.07.007_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0037-1613960","article-title":"A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways","volume":"84","author":"Tans","year":"2000","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.cll.2025.07.007_bib19","first-page":"4","article-title":"Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study","volume":"84","author":"Middeldorp","year":"2000","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.cll.2025.07.007_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2004.09.014","article-title":"Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature","volume":"116","author":"Cosman","year":"2005","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.cll.2025.07.007_bib21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0037-1615717","article-title":"The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial","volume":"85","author":"Hoibraaten","year":"2001","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.cll.2025.07.007_bib22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1046\/j.1365-2141.2002.03957.x","article-title":"Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women","volume":"119","author":"Post","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.cll.2025.07.007_bib23","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood-2003-04-1285","article-title":"Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial","volume":"103","author":"Kemmeren","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cll.2025.07.007_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.cll.2025.07.007_bib25","first-page":"9","article-title":"Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent Down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives","volume":"84","author":"Meijers","year":"2000","journal-title":"Thromb Haemost"},{"issue":"8045","key":"10.1016\/j.cll.2025.07.007_bib26","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0140-6736(77)90888-1","article-title":"Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen","volume":"2","author":"Meade","year":"1977","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cll.2025.07.007_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/13697137.2019.1703939","article-title":"Association of oral estradiol dose\/levels with coagulation measures in early\/late postmenopausal women","volume":"23","author":"Sriprasert","year":"2020","journal-title":"Climacteric"},{"key":"10.1016\/j.cll.2025.07.007_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.cll.2025.07.007_bib29","article-title":"Combined oral contraceptives: venous thrombosis","volume":"3","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cll.2025.07.007_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.cll.2025.07.007_bib31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/humrep\/deh612","article-title":"Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens","volume":"20","author":"van Vliet","year":"2005","journal-title":"Hum Reprod"},{"issue":"4","key":"10.1016\/j.cll.2025.07.007_bib32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0010-7824(79)90036-2","article-title":"Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women","volume":"19","author":"Humpel","year":"1979","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.cll.2025.07.007_bib33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/hematology.2024000591","article-title":"Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices","volume":"2024","author":"Skeith","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cll.2025.07.007_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"issue":"8935","key":"10.1016\/j.cll.2025.07.007_bib35","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation","volume":"344","author":"Vandenbroucke","year":"1994","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cll.2025.07.007_bib36","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.contraception.2016.05.014","article-title":"Combined hormonal contraceptive use among Obese women and risk for cardiovascular events: a systematic review","volume":"94","author":"Horton","year":"2016","journal-title":"Contraception"},{"issue":"8","key":"10.1016\/j.cll.2025.07.007_bib37","article-title":"Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke","volume":"2015","author":"Roach","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"10.1016\/j.cll.2025.07.007_bib38","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.cll.2025.07.007_bib39","first-page":"605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. JAMA"},{"issue":"9","key":"10.1016\/j.cll.2025.07.007_bib40","doi-asserted-by":"crossref","first-page":"680","DOI":"10.7326\/0003-4819-136-9-200205070-00011","article-title":"Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. preventive services task force","volume":"136","author":"Miller","year":"2002","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.cll.2025.07.007_bib41","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cll.2025.07.007_bib42","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/ATVBAHA.109.196022","article-title":"Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study","volume":"30","author":"Canonico","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7655","key":"10.1016\/j.cll.2025.07.007_bib43","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.39555.441944.BE","article-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis","volume":"336","author":"Canonico","year":"2008","journal-title":"BMJ"},{"issue":"7487","key":"10.1016\/j.cll.2025.07.007_bib44","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/bmj.38331.655347.8F","article-title":"Association between hormone replacement therapy and subsequent stroke: a meta-analysis","volume":"330","author":"Bath","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.cll.2025.07.007_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c2519","article-title":"Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study","volume":"340","author":"Renoux","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.cll.2025.07.007_bib46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1525-1497.2006.00389.x","article-title":"Brief report: coronary heart disease events associated with hormone therapy in younger and older women","volume":"21","author":"Salpeter","year":"2006","journal-title":"A meta-analysis J Gen Intern Med"},{"issue":"6","key":"10.1016\/j.cll.2025.07.007_bib47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.cll.2025.07.007_bib48","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.cll.2025.07.007_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejogrb.2004.06.038","article-title":"Changes in haemostasis during normal pregnancy","volume":"119","author":"Uchikova","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"10.1016\/j.cll.2025.07.007_bib50","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/ijlh.13472","article-title":"Trimester-specific thromboelastic values and coagulation activation markers in pregnancy compared across trimesters and compared to the nonpregnant state","volume":"43","author":"Shamshirsaz","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.cll.2025.07.007_bib51","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1111\/hae.12345","article-title":"Changes in factor XIII level during pregnancy","volume":"20","author":"Sharief","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.cll.2025.07.007_bib52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-2115(97)02734-6","article-title":"Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis","volume":"73","author":"Cerneca","year":"1997","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"10.1016\/j.cll.2025.07.007_bib53","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1055\/s-0038-1661167","article-title":"Haemostasis in normal pregnancy","volume":"52","author":"Stirling","year":"1984","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2025.07.007_bib54","first-page":"87","article-title":"Factor IX levels during pregnancy in a women with hemophilia B","volume":"11","author":"Briet","year":"1982"},{"issue":"4","key":"10.1016\/j.cll.2025.07.007_bib55","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1373\/clinchem.2016.265900","article-title":"Estimates of within-subject biological variation of protein C, Antithrombin, protein S free, protein S activity, and activated protein C resistance in pregnant women","volume":"63","author":"Kristoffersen","year":"2017","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.cll.2025.07.007_bib56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/MBC.0b013e3282f09835","article-title":"Haemostatic changes and acquired activated protein C resistance in normal pregnancy","volume":"18","author":"Mahieu","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.cll.2025.07.007_bib57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.thromres.2019.03.015","article-title":"Changes in laboratory markers of thrombotic risk early in the first trimester of pregnancy may be linked to an increase in estradiol and progesterone","volume":"178","author":"Bagot","year":"2019","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.cll.2025.07.007_bib58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12884-016-0937-5","article-title":"Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study","volume":"16","author":"Schock","year":"2016","journal-title":"BMC Pregnancy Childbirth"},{"issue":"5","key":"10.1016\/j.cll.2025.07.007_bib59","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: appropriate use and interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1016\/j.cll.2025.07.007_bib60","doi-asserted-by":"crossref","first-page":"233.e1-7","DOI":"10.1016\/j.ajog.2007.08.041","article-title":"Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study","volume":"198","author":"Jacobsen","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.cll.2025.07.007_bib61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/14767058.2014.913130","article-title":"Incidence of venous thromboembolism during pregnancy and the puerperium: a systematic review and meta-analysis","volume":"28","author":"Meng","year":"2015","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"22","key":"10.1016\/j.cll.2025.07.007_bib62","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy","volume":"2","author":"Bates","year":"2018","journal-title":"Blood Adv"},{"issue":"2 Suppl","key":"10.1016\/j.cll.2025.07.007_bib63","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.cll.2025.07.007_bib64","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1182\/bloodadvances.2022008648","article-title":"Obstetric and perioperative management of patients with factor XI deficiency: a retrospective observational study","volume":"7","author":"Handa","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.cll.2025.07.007_bib65","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/hematology.2023000475","article-title":"Management of pregnant women who have bleeding disorders","volume":"2023","author":"James","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.cll.2025.07.007_bib66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0306-4530(98)00022-5","article-title":"Hormonal aspects of postpartum depression","volume":"23","author":"Abou-Saleh","year":"1998","journal-title":"Psychoneuroendocrinology"},{"issue":"12","key":"10.1016\/j.cll.2025.07.007_bib67","first-page":"1602","article-title":"Haemostatic changes in the puerperium \u20186 weeks postpartum\u2019 (HIP study) - implication for maternal thromboembolism","volume":"116","author":"Saha","year":"2009"},{"issue":"5","key":"10.1016\/j.cll.2025.07.007_bib68","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/AOG.0000000000000230","article-title":"Postpartum venous thromboembolism: incidence and risk factors","volume":"123","author":"Tepper","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"14","key":"10.1016\/j.cll.2025.07.007_bib69","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa1311485","article-title":"Risk of a thrombotic event after the 6-week postpartum period","volume":"370","author":"Kamel","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cll.2025.07.007_bib70","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/jth.14882","article-title":"Systematic review of viscoelastic testing (TEG\/ROTEM) in obstetrics and recommendations from the women\u2019s SSC of the ISTH","volume":"18","author":"Amgalan","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.cll.2025.07.007_bib71","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/bja\/aes361","article-title":"Haemostatic monitoring during postpartum haemorrhage and implications for management","volume":"109","author":"Solomon","year":"2012","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.cll.2025.07.007_bib72","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/bjh.15524","article-title":"The use of viscoelastic haemostatic assays in the management of major bleeding: a British society for haematology guideline","volume":"182","author":"Curry","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2025.07.007_bib73","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgend Health"},{"issue":"5","key":"10.1016\/j.cll.2025.07.007_bib74","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1055\/s-0037-1615115","article-title":"The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning","volume":"79","author":"van Kesteren","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cll.2025.07.007_bib75","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/jth.15256","article-title":"Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen","volume":"19","author":"Scheres","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.cll.2025.07.007_bib76","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.maturitas.2009.01.009","article-title":"Effects of high dose oestrogen therapy on circulating inflammatory markers","volume":"62","author":"Wilson","year":"2009","journal-title":"Maturitas"},{"issue":"7","key":"10.1016\/j.cll.2025.07.007_bib77","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa262","article-title":"Global coagulation assays in transgender women on oral and transdermal estradiol therapy","volume":"105","author":"Lim","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.cll.2025.07.007_bib78","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M17-2785","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study","volume":"169","author":"Getahun","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cll.2025.07.007_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.741866","article-title":"Risk of venous thromboembolism in transgender people undergoing hormone feminizing therapy: a prevalence meta-analysis and meta-regression study","volume":"12","author":"Totaro","year":"2021","journal-title":"Front Endocrinol (LAUsanne)"},{"issue":"5","key":"10.1016\/j.cll.2025.07.007_bib80","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archinte.1984.00350170250041","article-title":"Myocardial infarction and severe thromboembolic complications. As seen in an estrogen-dependent transsexual","volume":"144","author":"Fortin","year":"1984","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cll.2025.07.007_bib81","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.thromres.2020.12.029","article-title":"Testosterone replacement therapy and the risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials","volume":"199","author":"Ayele","year":"2021","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.cll.2025.07.007_bib82","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/imj.14839","article-title":"Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals","volume":"51","author":"Nolan","year":"2021","journal-title":"Intern Med J"},{"issue":"5","key":"10.1016\/j.cll.2025.07.007_bib83","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/EJE-14-0891","article-title":"Complications of injectable testosterone undecanoate in routine clinical practice","volume":"172","author":"Middleton","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.cll.2025.07.007_bib84","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2021.09.005","article-title":"Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone","volume":"207","author":"Oakes","year":"2021","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/j.cll.2025.07.007_bib85","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1210\/jc.2003-030520","article-title":"Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people","volume":"88","author":"Toorians","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.cll.2025.07.007_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102197","article-title":"Thromboembolic risk with gender-affirming hormone therapy: potential role of global coagulation and fibrinolysis assays","volume":"7","author":"Bouck","year":"2023","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271225000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271225000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:22:19Z","timestamp":1761618139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271225000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0272271225000617"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2025.07.007","relation":{},"ISSN":["0272-2712"],"issn-type":[{"type":"print","value":"0272-2712"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Women\u2019s and Transgender Issues in Thrombosis and Hemostasis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}